| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0090-4295(00)01087-6 |
| P698 | PubMed publication ID | 11306379 |
| P50 | author | Klaus Jung | Q56956220 |
| P2093 | author name string | Hauptmann S | |
| Jung K | |||
| Loening SA | |||
| Schnorr D | |||
| Koenig F | |||
| Daniltchenko D | |||
| Gerhards S | |||
| P2860 | cites work | Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas | Q24649857 |
| Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer | Q28278066 | ||
| Matrix metalloproteinases and metastasis | Q33651977 | ||
| The accuracy of urinary cytology in daily practice | Q33672302 | ||
| Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications | Q33692926 | ||
| Urinary markers of malignancy. | Q33936517 | ||
| Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment | Q40642347 | ||
| Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic | Q41084451 | ||
| Expression and activity of MMPS and their regulators in ovarian cancer | Q61819259 | ||
| Software for illustrative presentation of basic clinical characteristics of laboratory tests--GraphROC for Windows | Q71767755 | ||
| Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma | Q71828023 | ||
| 31 Quantification of matrix metalloproteinases in tissue samples | Q72059246 | ||
| Gelatinase isoforms in urine from bladder cancer patients | Q74016740 | ||
| Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer | Q74404959 | ||
| Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas | Q74614385 | ||
| MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate | Q78027229 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 675-679 | |
| P577 | publication date | 2001-04-01 | |
| P1433 | published in | Urology | Q7900884 |
| P1476 | title | Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma | |
| P478 | volume | 57 |
| Q43943957 | A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer |
| Q47698874 | An Inexpensive, Point-of-Care Urine Test for Bladder Cancer in Patients Undergoing Hematuria Evaluation |
| Q39652187 | An inverse relationship between KAI1 expression, invasive ability, and MMP-2 expression and activity in bladder cancer cell lines |
| Q37536495 | Angiogenin contributes to bladder cancer tumorigenesis by DNMT3b-mediated MMP2 activation |
| Q39622272 | Antiproliferative factor decreases Akt phosphorylation and alters gene expression via CKAP4 in T24 bladder carcinoma cells |
| Q34079373 | Characterization of invading glioma cells using molecular analysis of leading-edge tissue |
| Q33253538 | Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder |
| Q40951466 | Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. |
| Q38798293 | Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. |
| Q34409699 | Identification of pro-inflammatory cytokines associated with muscle invasive bladder cancer; the roles of IL-5, IL-20, and IL-28A. |
| Q54411176 | Is a single nucleotide polymorphism a risk factor for lung cancer in the matrix metalloproteinase-2 promoter? |
| Q92646578 | MMP2 is associated with glioma malignancy and patient outcome |
| Q38882524 | Malignancy of bladder cancer cells is enhanced by tumor-associated fibroblasts through a multifaceted cytokine-chemokine loop |
| Q36125093 | Matrix Metalloproteinases and Bladder Cancer: What is New? |
| Q47377577 | Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer |
| Q81187567 | Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity |
| Q37864524 | Matrix metalloproteinases and their clinical relevance in urinary bladder cancer |
| Q37412311 | Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer |
| Q37551933 | Matrix metalloproteinases in the pathophysiology and progression of gynecological malignancies: could their inhibition be an effective therapeutic approach? |
| Q26744343 | Molecular substratification of bladder cancer: moving towards individualized patient management |
| Q35782279 | Non-invasive methods of bladder cancer detection |
| Q37398286 | Non-patient related variables affecting levels of vascular endothelial growth factor in urine biospecimens |
| Q36025140 | Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers |
| Q49135671 | Predictive and monitoring value of matrix metalloproteinase-9 for healing quality after sinus surgery |
| Q36216777 | Profiling of matrix metalloproteinases and tissue inhibitors of metalloproteinases proteins in bladder urothelial carcinoma |
| Q35810123 | Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature |
| Q73204461 | Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder |
| Q33869194 | Spotlight on differentially expressed genes in urinary bladder cancer. |
| Q46141142 | Strontium fructose 1,6-diphosphate alleviates early diabetic testopathy by suppressing abnormal testicular matrix metalloproteinase system in streptozocin-treated rats. |
| Q38778384 | The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells |
| Q35119047 | Transcriptome profiling of a multiple recurrent muscle-invasive urothelial carcinoma of the bladder by deep sequencing |
| Q33888492 | Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species |
| Q34721798 | Urinary high molecular weight matrix metalloproteinases as non-invasive biomarker for detection of bladder cancer |
| Q82981484 | Urinary matrix metalloproteinase activity is not significantly altered in patients with renal cell carcinoma |
| Q73739437 | Urinary matrix metalloproteinases as a potential screening test for gynecologic malignancies |
| Q38536270 | Urine biomarkers of schistosomiais and its associated bladder cancer |
Search more.